Hoba Therapeutics has successfully raised EUR 23 million (USD 25 million) in Series A financing to advance its development of therapeutic proteins for chronic neuropathic pain and hearing loss.
Information on the Target
Hoba Therapeutics is a Danish biotech firm established by Novo Holdings, specializing in the development of innovative therapeutic proteins. The company focuses on addressing chronic neuropathic pain and hearing loss, two conditions that significantly affect the quality of life for many patients. Through advanced research and technology, Hoba aims to create effective treatment options that can improve patient outcomes.
In securing EUR 23 million (USD 25 million) in its Series A financing first close, Hoba Therapeutics is well-positioned to advance its pipeline of therapeutic solutions. This funding will enable the company to further its clinical development and bring its promising products to market.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Denmark
Denmark has established itself as a strong player in the biotechnology sector, recognized for its innovative research and development capabilities. The country's favorable business environment, driven by a high level of investme
Similar Deals
Fåhraeus Startup & Growth Fund II (FSG) → Fida Biosystems
2025
Novo Holdings
invested in
Hoba Therapeutics
in 2023
in a Series A deal
Disclosed details
Transaction Size: $25M